A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients With Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment With CHOP-based Chemotherapy.
Phase of Trial: Phase III
Latest Information Update: 23 Oct 2017
At a glance
- Drugs Pralatrexate (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Allos Therapeutics; Spectrum Pharmaceuticals
- 16 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 16 Oct 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 11 Aug 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.